CD133 is a promising pan-cancer target, with 19 drugs currently in preclinical or phase I trials, most of which are antibody-based or CAR-T cell therapies, such as CD44/CD133-targeted CAR-T and OXS-1650 (Waldron et al, 2011; Zhai et al, 2024). The gene discussed is PROM1; the disease is cancer.